^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Syantra DX™ Breast Cancer test

    Company:
    Syantra
    Type:
    CE Marked
    Related tests:
    Details
    Evidence

    News

    5ms
    Syantra completes patent filing for ’new paradigm’ in early cancer detection (PRNewswire)
    "Syantra, Inc...announced it has filed an international patent application for its pioneering platform for the early detection of cancer and other diseases. The application also extends to methodology for the development of treatments and other methods of intervention."
    Patent
    |
    Syantra DX™ Breast Cancer test
    7ms
    Cancer Diagnostics firm Syantra raises $3.6M in Series A-1 round (Genomeweb)
    "Cancer diagnostics developer Syantra said Wednesday that it has raised C$4.9 million (US$3.6 million) in a Series A-1 financing round...Syantra said it will use the Series A-1 funding to fast-track the clinical validation and commercialization of the breast cancer test."
    Financing
    |
    Syantra DX™ Breast Cancer test
    7ms
    UCalgary, Cornell get $2.4M DoD Grant for trial of Syantra Breast Cancer Test (Genomeweb)
    "The University of Calgary is working with Cornell University to clinically validate a liquid biopsy test for the early detection of breast cancer with the support of approximately $2.4 million in funding from the US Department of Defense."
    Grant
    |
    Syantra DX™ Breast Cancer test
    almost2years
    Syantra receives CE Mark approval for their breast cancer test built on the Syantra DX™ liquid biopsy platform (Syantra Press Release)
    "Syantra announced...that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat."
    European regulatory
    |
    Syantra DX™ Breast Cancer test